Syndax shares sizzle on signal in entinostat/Keytruda combo effort
By Marie Powers
News Editor
News Editor
Despite "very interesting" preclinical data emerging on a heap of immuno-oncology molecules, "you still have to go into patients and show that it works," said Briggs Morrison, CEO of Syndax Pharmaceuticals Inc.
